RPR-109891
RPR-109891 is an orally active glycoprotein IIb/IIIa peptide antagonist. RPR-109891 can decrease platelet count and reduce platelet survival time. RPR-109891 can be used for the research of cardiovascular disease, such as myocardial infarction[1][2].
Product Specifications
CAS Number
169512-56-5
UNSPSC
12352005
Target
Integrin
Related Pathways
Cytoskeleton
Field of Research
Cardiovascular Disease
Smiles
O=C(CCCC1CCNCC1)N(CC)CC(N[C@@H](CC(O)=O)C(N[C@H](C(N)=O)CC2CCCCC2)=O)=O
Molecular Formula
C26H45N5O6
Molecular Weight
523.67
References & Citations
[1]Weiss DJ, et al. Platelet kinetics in dogs treated with a glycoprotein IIb/IIIa peptide antagonist. Toxicol Pathol. 2000 Mar-Apr;28 (2) :310-6.|[2]Giugliano RP, et al. First report of an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: results of the TIMI 15A and 15B trials. Am Heart J. 2000 Jul;140 (1) :81-93.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 1
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC401120-100 1x 100 µL
Ep-CAM / CD326 (EGP40/1120), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details